# Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)

> **NCT07025005** · PHASE4 · RECRUITING · sponsor: **Tanta University** · enrollment: 44 (estimated)

## Conditions studied

- Peripheral Neuropathy
- Multiple Myeloma, Neoplasms

## Interventions

- **DRUG:** Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet
- **DRUG:** Bortezomib + Lenalidomide + Dexamethasone

## Key facts

- **NCT ID:** NCT07025005
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07025005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07025005, "Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07025005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*